US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

48.06

+0.57331.21%

Post-market: 48.060.00000.00%17:19 EDT

Volume:5K

Turnover:217.17K

Market Cap:132.51M

PE:- -

High:48.19

Open:48.00

Low:47.87

Close:47.49

52wk High:48.78

52wk Low:27.34

Shares:2.76M

Float Shares:2.76M

Volume Ratio:1.29

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares

Cogent Biosciences Files for USD 400 Million At-the-Market Stock Offering

Cogent Biosciences - May Offer up to $400 Mln in Common Stock Through Guggenheim Securities - SEC Filing

THOMSON REUTERS

Sana Biotechnology Q2 Adjusted Loss Narrows, Beats Estimates

Bionano Genomics Q2 Revenue Rises on Increased Clinical Adoption

Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise

Metagenomi Q2 Net Loss Widens Cash Runway Seen Through 2027

Harrow Q2 Revenue Slightly Beats Estimates

Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan

Rocket Pharmaceuticals Posts Q2 Profit Helped by PRV Sale

Olema Pharmaceuticals Q2 Net Loss Widens on Higher Clinical Trial Spending

Biohaven Q2 Net Loss Narrows on Lower R&D Spend

Septerna Q2 Revenue Beats Analyst Estimates, Driven by Novo Nordisk Partnership

Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa

MT Newswires Live

Cogent Biosciences Q2 Loss Widens

MT Newswires Live

Cogent Biosciences Q2 Net Income USD -96.405 Million

Cogent Biosciences Q2 Operating Expenses USD 102.638 Million

THOMSON REUTERS

Spyre Therapeutics Announces Launch of Spy772 Program and Initiation of Phase 2 Skylight Trial in Hidradenitis Suppurativa

THOMSON REUTERS

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LFSC/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":48.0628,"timestamp":1787688000000,"preClose":47.4895,"halted":0,"volume":4525,"hourTrading":{"tag":"盘后","latestPrice":48.0628,"preClose":48.0628,"latestTime":"17:19 EDT","volume":118,"amount":5577.491368,"timestamp":1787692741601,"change":0,"changeRate":0,"amplitude":0.002022},"delay":0,"changeRate":0.012072142263026633,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"Post-Mkt","change":0.5733,"latestTime":"08-25 18:18:50 EDT","open":48,"high":48.19,"low":47.87,"amount":217171.35675,"amplitude":0.006738,"askPrice":72.16,"askSize":200,"bidPrice":47.48,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":47.4895,"sharesOutstanding":2657035,"nav":47.8,"aum":131786273,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":48.0628,"preClose":48.0628,"latestTime":"17:19 EDT","volume":118,"amount":5577.491368,"timestamp":1787692741601,"change":0,"changeRate":0,"amplitude":0.002022},"volumeRatio":1.286754},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.286754,"shares":2757035,"dividePrice":0,"high":48.19,"amplitude":0.006738,"preClose":47.4895,"low":47.87,"week52Low":27.3402,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":48.0628,"committee":-0.99005,"eps":0,"divideRate":0,"volume":4525,"delay":0,"ttmEps":0,"open":48,"prevYearClose":36.6147,"prevWeekClose":47.7953,"prevMonthClose":45.55,"prevQuarterClose":45.2033,"fiveDayClose":47.489,"twentyDayClose":45.3952,"sixtyDayClose":39.3901},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658696533","title":"Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2658696533","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658696533?lang=en_us&edition=fundamental","pubTime":"2026-08-11 09:32","pubTimestamp":1786411952,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common sharesSpyre Therapeutics director Jeffrey W. Albers exercised stock options to buy 5,000 common shares at USD 10.39","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL7DPBBq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658339952","title":"Cogent Biosciences Files for USD 400 Million At-the-Market Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2658339952","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658339952?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:20","pubTimestamp":1786396815,"startTime":"0","endTime":"0","summary":"Cogent Biosciences files for USD 400 million at-the-market stock offeringCogent Biosciences set an at-the-market equity offering of up to USD 400 million under its sales agreement with Guggenheim Secu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL5kPmbQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","LFSC","COGT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952825","title":"Cogent Biosciences - May Offer up to $400 Mln in Common Stock Through Guggenheim Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952825?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:18","pubTimestamp":1786396717,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471SE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","CANC","BK4139","BK4505","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951818","title":"Sana Biotechnology Q2 Adjusted Loss Narrows, Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951818","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951818?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:24","pubTimestamp":1786393458,"startTime":"0","endTime":"0","summary":"Sana Biotechnology Q2 adjusted loss narrows, beats estimatesOverviewCell therapy developer's Q2 adjusted loss per share beat analyst expectationsQ2 adjusted net loss also beat analyst expectationsComp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470W1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","CANC","BK4139","SANA","BK4505","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951894","title":"Bionano Genomics Q2 Revenue Rises on Increased Clinical Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951894","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951894?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:24","pubTimestamp":1786393456,"startTime":"0","endTime":"0","summary":"Bionano Genomics Q2 revenue rises on increased clinical adoptionOverviewGenome analysis solutions provider's Q2 revenue rose 21% yr/yr to $8.2 mlnGross margin for Q2 improved to 53% from 52% a year ea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470WJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNGO","CANC","BK4575","BK4121","BK4505","BK4139","QTRX","COGT","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658518889","title":"Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2658518889","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658518889?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:22","pubTimestamp":1786393334,"startTime":"0","endTime":"0","summary":"Cell therapy developer ProKidney's Q2 operating loss widens as trial costs riseOverviewU.S. cell therapy developer's Q2 operating expenses rose, driven by clinical study and manufacturing costsNet los","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470W0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4505","CANC","PROK","COGT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959032","title":"Metagenomi Q2 Net Loss Widens Cash Runway Seen Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959032","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959032?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:21","pubTimestamp":1786393289,"startTime":"0","endTime":"0","summary":"Metagenomi Q2 net loss widens cash runway seen through 2027OverviewGenome editing firm's Q2 net loss widened to $27.5 mln, loss per share was $0.73Company ended Q2 with $120.7 mln in cash, expects run","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGX","TBPH","LFSC","BK4007","CANC","BK4139","BK4505","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658295927","title":"Harrow Q2 Revenue Slightly Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658295927","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658295927?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:19","pubTimestamp":1786393164,"startTime":"0","endTime":"0","summary":"Harrow Q2 revenue slightly beats estimatesOverviewOphthalmic drug maker's Q2 revenue rose 11% yr/yr, slightly beating analyst expectationsCompany posted net loss per share of $0.46, down from profit l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470WT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","HRTX","BK4139","LFSC","BK4007","COGT","HROW","CANC","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658599689","title":"Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2658599689","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658599689?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:13","pubTimestamp":1786392812,"startTime":"0","endTime":"0","summary":"Guardant Health grants 46,044 RSUs to 149 new employees under inducement planGuardant Health set inducement RSU grants covering 46,044 common shares for 149 new non-executive hires, with an Aug. 3, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL208d3j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNMX","PTH","FFOX","GNOM","LFSC","BK4585","BK4535","LU0889565916.HKD","HELX","BK4551","LU0320765992.SGD","GDOC","LU0109394709.USD","GH","BK4588","BK4196","EKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658895955","title":"Rocket Pharmaceuticals Posts Q2 Profit Helped by PRV Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2658895955","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658895955?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:10","pubTimestamp":1786392651,"startTime":"0","endTime":"0","summary":"Rocket Pharmaceuticals posts Q2 profit helped by PRV saleOverviewUS biotech firm reported Q2 net income after KRESLADI approval and PRV saleR&D and G&A expenses fell yr/yr due to lower headcount and c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470UW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4505","CANC","RCKT","TBPH","COGT","QTRX","BK4139","BK4007","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959530","title":"Olema Pharmaceuticals Q2 Net Loss Widens on Higher Clinical Trial Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959530","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959530?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:10","pubTimestamp":1786392606,"startTime":"0","endTime":"0","summary":"Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spendingOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr due to higher clinical development spendingCompany completed enr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470V3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","BK4139","LFSC","OLMA","BK4505","COGT","TBPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959562","title":"Biohaven Q2 Net Loss Narrows on Lower R&D Spend","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959562","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959562?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:09","pubTimestamp":1786392543,"startTime":"0","endTime":"0","summary":"Biohaven Q2 net loss narrows on lower R&D spendOverviewU.S. biopharma firm's Q2 net loss narrowed yr/yr on lower R&D and preclinical spendingQ2 operating expenses fell sharply after strategic repriori","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BHVN","LFSC","BK4505","BK4007","BK4139","CANC","LU1093756325.SGD","COGT","TBPH","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658295935","title":"Septerna Q2 Revenue Beats Analyst Estimates, Driven by Novo Nordisk Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2658295935","media":"Reuters","labels":["corporation","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658295935?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:08","pubTimestamp":1786392529,"startTime":"0","endTime":"0","summary":"Septerna Q2 revenue beats analyst estimates, driven by Novo Nordisk partnershipOverviewUS biotechnology firm's Q2 revenue rose and beat analyst expectationsNet loss for Q2 narrowed compared to prior y","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470V5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4505","QTRX","BK4139","BK4007","COGT","HRTX","CANC","SEPN","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658893427","title":"Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2658893427","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658893427?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:58","pubTimestamp":1786370315,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics  said Monday that it has launched SPY772, a program that combines SPY072, a long-acting anti-TL1A antibody, and SPY007, a novel long-acting anti-IL-17A/F antibody in preclinical development.The program is designed to treat patients with Hidradenitis Suppurativa, which is a skin condition that causes painful lumps deep within the skin, Spyre said.The clinical-stage company said it has initiated a mid-stage proof-of-concept trial evaluating dual inhibition of TL1A and IL-17A/F to treat Hidradenitis Suppurativa. The study is expected to enroll 150 adults. Topline results are expected late next year or early 2028.Price: 104.61, Change: -0.30, Percent Change: -0.29","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SYRE","LENZ","BK4139","BK4539","LFSC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658393839","title":"Cogent Biosciences Q2 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2658393839","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658393839?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:37","pubTimestamp":1786365426,"startTime":"0","endTime":"0","summary":"Cogent Biosciences  reported Monday its Q2 loss widened to $96.4 million from a loss of $73.5 million a year earlier.Analysts polled by FactSet expected a loss of $98 million.As of June 30, the company said it had $792.3 million in cash, cash equivalents and marketable securities and expected it could fund operations into late 2028.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","BK4532","BK4139","LU1670627923.USD","CCOI","LFSC","LU1670628061.USD","COGT","BK4089","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658365389","title":"Cogent Biosciences Q2 Net Income USD -96.405 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658365389","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658365389?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:13","pubTimestamp":1786363990,"startTime":"0","endTime":"0","summary":"Aug 10 (Reuters) - Cogent Biosciences Q2 income from operations USD -102.638 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 10-AUG-202611:47:52.75 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nRSDb7xYB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","CANC","COGT","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658923935","title":"Cogent Biosciences Q2 Operating Expenses USD 102.638 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658923935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658923935?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLXR5T2QR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","LFSC","CANC","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945935","title":"Spyre Therapeutics Announces Launch of Spy772 Program and Initiation of Phase 2 Skylight Trial in Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945935?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA5HMVSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993661","title":"Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993661","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993661?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"SPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation Phase 2 SKYLIGHT tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341779/0/en/spyre-therapeutics-announces-launch-of-spy772-program-and-initiation-of-phase-2-skylight-trial-in-hidradenitis-suppurativa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4539","BK4139","LENZ","LFSC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660616","title":"Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660616","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660616?lang=en_us&edition=fundamental","pubTime":"2026-08-10 07:38","pubTimestamp":1786318701,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported second-quarter 2026 results showing a net loss of US$15.15 million, up from US$9.29 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$0.23 from US$0.15.\nFor the first half of 2026, the company’s net loss expanded to US$34.11 million versus US$20.10 million in the prior-year period, highlighting a meaningful increase in cash burn and pressure on its financial profile.\nWe’ll now examine how this widening net...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GH","LU0109394709.USD","BK4007","EKG","FFOX","BK4535","BK4551","PTH","LU0889565916.HKD","GNMX","LFSC","GDOC","GNOM","HELX","BK4539","PSIL","LU0320765992.SGD","BK4196","BK4585","GHRS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":196,"code":"91000000","status":"200"}]}}